Upharmacia October 2017
PHARMA MARKET NEWS
Indar will Establish Joint Enterprise in Azerbaijan
Indar, the Ukrainian producer of insulin, has signed the Memorandum with Azerbaijani Investment Company on establishing a joint pharmaceutical venture in Pirallahy Industrial Park. The company will produce infusion and injection solutions. The construction of production facilities will start in 2018 and will last for 2 years. The cost of the project is to amount USD 17 mio. The enterprise will create 350 jobs.
Pirallahy Industrial Park was created in 2016 following the President’ s Order to promote the development of the local pharmaceutical industry. Currently, 3 companies are constructing facilities in the Park. The residents of the Park are freed from paying different taxes for 7 years.
Indar was established in 1997 by the government. 70 % of the company belongs to the State company Ukrmedprom. The company is included in the list of state objects, which have a strategic importance for the economy and state security.
BCPP Plans to Launch 4-6 New
Drugs by the end of 2017
Borshchahivskiy Chemical-Pharmaceutical Plant( BCCP) plans to launch onto the market from 4 to 6 new drugs by the year-end, the company’ s reconstruction and development Director sated. The preparations are related to cardiovascular diseases and neurology. Currently, BCPP has about 25 drugs in development.
The market of cardio drugs amounted about UAH 7,1 bn in 2016. In 9M 2017, BCCP was 20 th company on Ukrainian drug market by sales. In 2016, the company doubled its net profit vs 2015 to UAH 118.7 mio.
Galychpharm
Received GMP
Certificate to Produce Tablets
Galychpharm company received Ukrainian GMP certificate to produce drugs in form of tablets. Lately, the company reconstructed the tablet-packing shop and installed more than 14 units of new equipment. Galychpharm is a producer of about 90 herbal-based drugs and phyto-chemical substances. Some of is drugs are produced in a form of tablets, such as Mucaltine, Streptocide, Asparkam etc.
Galychpharm is a Lviv-based part of Arterium Corporation, which also includes Kyivmedpreparat company. In 9M 2017, Arterium corporation held the second place on the Ukrainian drugs market by retail sales.
Lekhim Launches Veterinary Direction
Lekhim group of companies started producing veterinary drugs on the base of Technolog company. Thus, the company, the main focus of which are cardiology and drugs for alimentary tract, opened the new direction of its development. Lekhim started developing the veterinary direction in 2016 and now has 3 veterinary drugs to produce.
Lekhim group includes JSC Lekhim( Kyiv), JSC Technolog( Uman) and JSC Lekhim-Kharkiv( Kharkiv). In Oct 2017, Technolog plant received the EU GMP certificate to produce drugs.
Darnitsa Increased its Net Profits
Pharmaceutical Firm Darnitsa increased its net profits by 5 % in 3Q 2017 vs the same period in 2016 to UAH 252.3 mio.
Gross profit for the same period grew by 19 % to UAH 998.6 mio, NSSMC stated.
The company was the third largest local manufacturer in 2016 following Farmak and Arterium.
More Than 70 % of Medicines Bought Directly From Suppliers
The UNDP has analyzed the procurement it conducted with the funds of 2016 state budget.
According to the results, share of medicines bought directly from manufacturers comprised 71 %, in contrast to 90 % of the MoH tenders won by distributors in 2014 and earlier years- before the international procurement of medicines was introduced.
6 www. upharma-c. com